~~<i id='16CCB97A2C'><strike id='16CCB97A2C'><tt id='16CCB97A2C'><pre id='16CCB97A2C'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：hotspot 2025-10-06 13:59:38 Page View：12

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： HIPAA doesn't protect reproductive records from prosecutors
Next article： Walensky prepares to leave CDC — and Congress — behind

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

He's 19 months old and has one of the world’s rarest diseases

LucasGuo,aboywitharareneurologicalconditioncalledZTTK,isencouragedbyhisfather,NathanGuo,andmother,Ad

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

AdobeAcommonlyusedtreatmentforpeoplewithkneeosteoarthritisisbarelymoreeffectivethantheplaceboeffecti